Business
Voting rights and capital
Voting rights and capital.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n02 April 2007\n\n\n\n\n Hikma Pharmaceuticals PLC - Voting Rights and Capital\n\nLONDON, 2 April 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifies\nthe market that as at 31 March 2007 its capital consists of 169,137,407 ordinary\nshares with voting rights. There are no shares held in treasury.\n\nThe above figure (169,137,407) may be used by shareholders as the denominator\nfor the calculations by which they will determine if they are required to notify\ntheir interest in, or a change to their interest in, Hikma Pharmaceuticals PLC\nunder the FSA's Disclosure and Transparency Rules.\n\n - ENDS -\nEnquiries:\n\nHikma Pharmaceuticals PLC\n\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\n\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\nAbout Hikma\nHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: Generic, Branded and Injectable\nPharmaceuticals. Hikma's operations are based principally in the United States,\nthe Middle East and North Africa ('MENA') region and Europe. In 2006, the Group\nhad revenue of $317 million and profit attributable to shareholders of $54.5\nmillion. For news and other information, please visit www.hikma.com.\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":1803,"tagName":"div"}]